CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net income (loss)	$ 36,326,199	$ (5,254,652)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Depreciation expense	8,260	12,753
Gain on debt extinguishment	(40,802,730)	(2,434,661)
Decrease in fair value of derivative liabilities	0	(948)
Amortization of discount on notes payable	1,261,156	2,064,774
Accrued interest on patents purchased	198,000	123,233
Amortization of patents and acquired contracts	776,745	1,217,985
Stock-based compensation	334,796	545,626
Changes in operating assets and liabilities
Accounts receivable	14,824	8,880
Prepaid expenses and other current assets	440,518	(646,943)
Deferred expenses	97,409	(27,391)
Deposits and other assets	(1,865)	0
Accounts payable	367,658	777,559
Accrued expenses and other current liabilities	221,563	407,267
Deferred revenue	(1,246,429)	450,000
Net cash used in operating activities	(2,003,896)	(2,756,518)
Cash flows from financing activities
Proceeds from issuance of preferred stock, net of issuance costs	0	5,221,998
Proceeds from issuance of common stock, net of issuance costs	0	1,182,278
Proceeds from short-term notes payable, related parties	530,000	0
Payments on senior notes payable	0	(1,640,016)
Redemption of preferred stock	0	(2,500,000)
Payments on related party note payable	0	(50,000)
Net cash provided by financing activities	530,000	2,214,260
Net decrease in cash and cash equivalents	(1,473,896)	(542,258)
Cash and cash equivalents, beginning of period	1,476,774	554,556
Cash and cash equivalents, end of period	2,878	12,298
Supplemental disclosures of cash flow information
Cash paid for interest	0	613,600
Supplemental disclosures of non-cash investing and financing activities
Fair value of common stock warrants	$ 341,535	$ 4,154,620